Product news from the 10/31/06 News Brief

Share this article:
The FDA has approved Novartis’ Tyzeka (telbivudine) for patients with chronic hepatitis B. Alpharma won FDA approval for its 80 mg dosage strength of chronic pain treatment Kadian (morphine sulfate). The company expects to launch this new dosage strength during the fourth-quarter of 2006. Kadian is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.